Area of research
Genetics · Public Health, Environmental and Occupational Health
Research interest
Research interests include Inflammatory Bowel Disease, Pregnancy and Medication Impact, Gallbladder and Bile Duct Disorders, and Microscopic Colitis.
Surgical treatment of a patient with complications after endovascular procedure for type B aortic dissection (a clinical case report)
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
Elevated lactate/albumin ratio as a novel predictor of in-hospital mortality in hospitalized cirrhotics
Inflammatory bowel disease in families with four or more affected first-degree relatives
COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience
Detection of elusive polyps using a large-scale artificial intelligence system (with videos)
Anemia can predict the prognosis of colorectal cancer in the pre-operative stage: a retrospective analysis
Three-months duration of fully-covered metal stent for refractory dominant extra-hepatic biliary stricture among primary sclerosing cholangitis patients: efficacy and safety
Nonalcoholic fatty liver disease and the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis: the hidden danger
Long-Term Safety of Endoscopic Biliary Stents for Cholangitis Complicating Choledocholithiasis: A Multi-Center Study
DOP57 Vedolizumab has similar efficacy rates in young and elderly patients: A binational, multicentre, retrospective case–control study
Sleep Disturbances Can Be Prospectively Observed in Patients with an Inactive Inflammatory Bowel Disease
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease
Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial
Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Pregnancy and the Immune System: General Overview and the Gastroenterological Perspective
Mutant KRAS is a druggable target for pancreatic cancer